CTX110 for B-Cell Cancers
Recruiting at 32 trial locations
CT
Overseen ByClinical Trials
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: CRISPR Therapeutics AG
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
This trial tests CTX110, a treatment using modified immune cells from healthy donors, on patients with B-cell cancers that have not responded to other treatments. The immune cells are altered in a lab to better attack cancer cells using gene-editing technology.
Research Team
AW
Annie Weaver, PhD
Principal Investigator
CRISPR Therapeutics
Eligibility Criteria
This trial is for adults with B-cell malignancies like non-Hodgkin's lymphoma or acute lymphoblastic leukemia that didn't respond to at least two prior treatments. Participants must be in good physical condition, have well-functioning major organs, and not be pregnant or breastfeeding. They should agree to use contraception and join a follow-up study.Inclusion Criteria
My kidney, liver, heart, and lung functions are all good.
I am fully active or can carry out light work.
Agree to participate in an additional long-term follow-up study after completion of this study.
See 3 more
Exclusion Criteria
I have had cancer before, but it was either skin cancer treated by surgery, cervical in situ carcinoma, or any cancer in remission for 5+ years.
I do not have an ongoing serious infection requiring IV drugs.
I have had a stem cell transplant from a donor for my lymphoma.
See 9 more
Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Lymphodepleting Chemotherapy
Participants receive lymphodepleting chemotherapy prior to CTX110 infusion
1-2 weeks
Treatment
CTX110 is administered by IV infusion
1 day
Follow-up
Participants are monitored for safety and effectiveness after treatment
60 months
Treatment Details
Interventions
- CTX110
Trial Overview The CARBON trial is testing the safety and effectiveness of CTX110, a new therapy for people with certain blood cancers that have come back or haven't responded to treatment. It's an early-phase study where everyone gets the same experimental treatment.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: CTX110Experimental Treatment1 Intervention
Administered by IV infusion following lymphodepleting chemotherapy.
Find a Clinic Near You
Who Is Running the Clinical Trial?
CRISPR Therapeutics AG
Lead Sponsor
Trials
9
Recruited
640+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.